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Hypoglycemia is a common metabolic emergency representing an imbalance in
the energy demands of the brain and the available glucose supply despite normal
arterial oxygen tension.
1,2 This imbalance results in autonomic symptoms (e.g.,
anxiety, sweating, and tremulousness) and neurologic symptoms (e.g., weakness,
fatigue, and mental confusion).
1,3 Approximately 7% of patients presenting to the
emergency department (ED) with complaints of altered mental status have
hypoglycemia, and 20% of patients with diabetes mellitus (DM) treated with
insulin or anti-diabetic agents (ADAs) will have symptoms related to hypogly-
cemia requiring ED evaluation and treatment.
4 Severe hypoglycemia, if unreco-
gnized and untreated, can result in neural damage, impaired cognitive function,
coma, seizures, or death.
4-7 Single and recurrent episodes of hypoglycemia may
cause physical and psychological morbidity and increase the risk of death, but
may also prevent euglycemia.
8 Risk factors placing diabetic patients at greater risk
for developing hypoglycemia include male gender, adolescence or age > 55,
increased amounts of exercise or activity, decreased carbohydrate intake, alcohol
consumption, impaired renal or liver function, intensive glucose control, changes
in insulin or ADA regimen, infection, significant comorbidities, and poly-
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Purpose: Severe hypoglycemia can result in neural damage, impaired cognitive function, coma, seizures, or death.
The decision to admit diabetic patients after initial treatment in the emergency department remains unclear. Our
purpose is to identify risk factors for developing recurrent hypoglycemia in diabetic patients admitted for severe
hypoglycemia. Materials and Methods: We reviewed the records of 233 subjects (92 males, 141 females; mean
age, 74.1 ± 9.8 years) with type 2 diabetes treated at a tertiary care teaching hospital and hospitalized for severe
hypoglycemia. Results: Seventy-four (31.8%) patients were categorized with recurrent hypoglycemia and 159
(68.2%) with non-recurrent. Multivariate logistic regression analysis revealed that patients with loss of a recent
meal, coronary artery disease, infection, and poor renal function (lower estimated glomerular filtration rate) were at
risk for recurrent hypoglycemia. The use of calcium-channel blockers appeared to be a protective factor for the
development of recurrent hypoglycemia. Conclusion: There may be a subset of patients with severe hypoglycemia
and certain risk factors for recurrent hypoglycemia that should be admitted. 
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INTRODUCTIONpharmacy.
2,9,10 
Patients with severe hypoglycemia and who are at risk
for recurrent hypoglycemia should be admitted, while
those with a rapidly normalized glucose level and not at
risk may not require admission. The purpose of this study
is to identify risk factors for recurrent hypoglycemia in
diabetic patients hospitalized for severe hypoglycemia. 
Study population and data collection
This retrospective, observational chart review was conduct-
ed at a 1,600-bed, tertiary-level, teaching hospital with an
annual ED volume of 90,000 patients. Patients presenting to
the ED during a 4-year period from January 2003 to
December 2006 and diagnosed with DM and hospitalized
for severe hypoglycemia were enrolled. As this study in-
volved medical records obtained as part of routine ED
care, the Institutional Review Board determined that no
patient consent was required. Inclusion criteria were
patients diagnosed with type 2 DM, either by previous
medical records or by clinical criteria described previously,
11
and followed in the diabetes clinic for at least 2 months. 
We defined severe hypoglycemia using the American
Diabetes Association criteria as an event requiring assi-
stance of another person to actively administer carbohy-
drate, glucagon, or other resuscitative action. These epi-
sodes may be associated with sufficient neuroglycopenia
to induce seizure or coma, and neurological recovery is
attributable to the restoration of the blood glucose level.
12
The hospital database is an observational database
including data on all patients hospitalized at the study
institution. Patient records coded for ICD9 251.× and
250.× were retrieved, and patient records not fitting the
inclusion criteria were excluded. For analysis, patients
were divided into 2 groups. The study group consisted of
admitted diabetic patients with hypoglycemic episodes
during the first 48 hours of admission. The control group
consisted of admitted diabetic patients without hypo-
glycemic episodes after admission.
Variables and outcome measures
Each chart was reviewed by one of the five authors and
data abstracted to a standardized collection sheet developed
by the authors. Demographic data abstracted included age,
gender, duration of DM (years), hospital days, body mass
index (BMI), comorbidities, carbohydrate intake, loss of a
recent meal (defined as a history of missing a meal recently
or decreased food intake before ED visit), current medica-
tions, laboratory testing, and initial serum glucose level. 
Laboratory studies abstracted were white blood count
(WBC), hemoglobin, platelets, aspartate transaminase,
blood urea nitrogen (BUN), serum creatinine, hemoglobin
A1c (HbA1c), albumin, total cholesterol, triglyceride, total
protein, and uric acid. Glomerular filtration rate (GFR) was
estimated using the Modification of Diet in Renal Disease
study formula as follows: GFR = 186.3 × (serum creati-
nine
-1.154)×(age
-0.203)×1.212 (if black)×0.742 (if female).
13
Current medications included benzodiazepines, renin-
angiotensin system blockers (RASBs), calcium channel
blockers (CCB), alpha-blockers, beta-blockers, diuretics,
insulin, and oral ADAs. We defined polypharmacy as
more than 5 of these medications.
Comorbidities included hypertension, coronary artery
disease (CAD), congestive heart failure (CHF), chronic
obstructive pulmonary disease (COPD), dyslipidemia,
infection, end-stage renal disease (ESRD), cancer, cirrhosis,
and alcoholism.
The main outcome measure was the development of
recurrent symptomatic hypoglycemia (serum glucose < 70
mg/dL) or a symptomatic episode that fulfilled Whipple’s
triad (low serum glucose, hypoglycemic symptoms, and
symptom resolution after glucose administration) within
48 hours after admission for severe hypoglycemia diag-
nosed in the ED. 
Statistical analysis
Continuous data was expressed as mean ± standard devia-
tion (SD) and tested with Student t-test. Categorical data
was expressed as frequencies (%) and tested with Chi-
Square test or Fisher’s exact test. Univariate logistic
regression analysis was used to determine the possible risk
factors associated with recurrent hypoglycemia. To access
the adjusted effect of different variables, we selected the
variables either having a p value < 0.2 in the initial univa-
riate results, or clinical important factors into multivariate
logistic regression analysis. Multivariate logistic regression
analysis with stepwise forward selection was used to control
possible confounding variables and to determine the risk
factors for developing recurrent hypoglycemia during
hospitalization. Data was analyzed using SAS 9.0 (SAS
Institute Inc., Cary, NC, USA) and a p value < 0.05 was
considered statistically significant.
We identified 504 patients presenting to the ED with severe
hypoglycemia during the study period. Of these, 244
patients were hospitalized (Fig. 1). The remaining 260
patients’ medical records were also examined and none of
those patients were readmitted to the ED for hypoglycemia.
Eleven patients did not have type 2 DM or incomplete
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MATERIALS AND METHODS
RESULTSinformation and were excluded from analysis. Of the
remaining 233 study patients (92 males and 141 females;
mean age, 74.1 ± 9.8 years), 74 (31.8%) were categorized
as recurrent hypoglycemia and 159 (68.2%) were catego-
rized as non-recurrent hypoglycemia. All patients studied
were diagnosed as type 2 DM.
Table 1 presents the comparison of the basic characteri-
stics and laboratory results for the two study groups. There
were significant differences of loss of a recent meal, dura-
tion of diabetes, duration of hospital stay, initial serum
glucose level, WBC, hemoglobin, estimated GFR, serum
creatinine, BUN, and albumin among the two groups (p <
0.05). The recurrent hypoglycemia group had a higher
percentage of patients (59.5%) with loss of a recent meal
(p < 0.001). Patients in the recurrent hypoglycemia group
had a significantly longer duration of diabetes and hospital
stays than the non-recurrent group. WBC, serum creatinine,
and BUN were significantly higher in the recurrent hypo-
glycemia group as compared to the non-recurrent group.
Initial serum glucose level, estimated GFR, and albumin
were significantly lower in the recurrent hypoglycemia
group as compared to the non-recurrent group. 
Table 2 presents the medications and comorbidities data.
The recurrent hypoglycemia group had significantly higher
percentages of patients taking benzodiazepines, alpha-
blocker agents, beta-blocker agents, diuretics, and polyphar-
macy as compared to the non-recurrent group; however,
the recurrent hypoglycemia group had a significantly
Risk Factors for Recurrent Hypoglycemia
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Fig. 1.Patient enrollment.
Table 1. Demographic and Laboratory Data of the Two Study Groups
Non-recurrent group Recurrent group
pvalue
(n = 159) (n = 74)
Age (yr) 74.09 ± 10.43 74.20 ± 8.92 0.939
Male  60 (37.7) 32 (43.2) 0.472
Loss of recent meal 47 (29.6) 44 (59.5) < 0.001*
Previous hypoglycemia 33 (20.8) 22 (29.7) 0.139
Duration of diabetes (yrs) 12.41 ± 8.07 15.35 ± 8.29 0.011*
Body mass index (kg/m
2) 25.55 ± 3.18  25.77 ± 3.68  0.642
Hospital stay (days)  5.78 ± 5.11 9.57 ± 7.10 < 0.001*
White blood cell count (cells/µL)  8,405.12 ± 2,863.87 11,078.11 ± 9,605.95 0.021*
Hemoglobin (g/dL) 11.19 ± 1.75 10.42 ± 2.01 0.003*
Platelets (cells/µL)  252,566.04 ± 96,365.18 266,435.14 ± 110,128.51 0.330
Aspartate transaminase (mg/dL)  28.09 ± 20.04 27.82 ± 20.20 0.936
Estimated GFR (mL/min)  61.78 ± 38.04 31.34 ± 27.76 < 0.001*
Serum creatinine (mg/dL)  1.42 ± 1.26  3.00 ± 2.22 < 0.001*
BUN (mg/dL)  25.05 ± 14.49  37.77 ± 24.07 < 0.001*
Sodium (mg/dL) 135.68 ± 5.74 134.32 ± 7.23 0.159
Potassium (mg/dL) 3.76 ± 8.16 3.91 ± 8.73 0.185
HbA1c (mg/dL)  11.19 ± 1.75 10.42 ± 2.01 0.519
Albumin (mg/dL)  3.58 ± 0.68  3.34 ± 0.73 0.016*
Total cholesterol(mg/dL) 150.22 ± 45.85 150.64 ± 51.20 0.950
Triglyceride(mg/dL) 114.24 ± 60.91 120.12 ± 91.77 0.563
Total protein(mg/dL) 6.37 ± 0.79 6.35 ± 0.80 0.795
Uric acid (mg/dL) 5.7 ± 2.0 5.9 ± 1.9 0.389
BUN, blood urea nitrogen; GFR, glomerular filtration rate; HbA1c, hemoglobin A1c.
Continuous data expressed as mean ± SD, and categorical data expressed as number (%).
*p< 0.05.lower percentage of CCBs compared to the non-recurrent
group (21.6% vs. 36.1%, p = 0.033). When examining
comorbidities, the recurrent hypoglycemia group was found
to have a significantly higher prevalence of CAD (60.8%)
and infection (47.3%) as compared to the non-recurrent
group. There was no statistical significance regarding the
different types of oral anti-diabetic medications between
the two groups.  
Univariate logistic regression analysis for possible risk
factors associated with recurrent hypoglycemia for the 233
subjects are presented in Table 3. Significant risk factors
for the development of recurrent hypoglycemia were loss
of a recent meal, duration of diabetes, initial serum glucose
level, WBC count, hemoglobin, estimated GFR, serum
creatinine, BUN, albumin, the use of benzodiazepines,
alpha-blocker agents, beta-blocker agents, and diuretics,
polypharmacy, and the presence of CAD and infection.
The use of CCBs showed a protective effect. 
After controlling for age and gender, as shown in Table 4,
multivariate logistic regression analysis found that patients
with loss of a recent meal (OR = 3.93; 95% CI, 1.82-8.50; p
< 0.001), who had CAD (OR = 2.30; 95% CI, 1.04-5.10; p
= 0.041) or infection (OR = 2.97; 95% CI, 1.08-6.30; p =
0.032), or who had a renal insufficiency (lower estimated
GFR) (OR = 0.97; 95% CI, 0.95-0.98; p < 0.001) were at
risk for recurrent hypoglycemia. The use of CCBs (OR =
0.19; 95% CI, 0.08-0.46; p < 0.001) was a protective factor
the development of recurrent hypoglycemia.
The purpose of this study is to identify risk factors for
recurrent hypoglycemia in diabetic patients hospitalized
Yen-Yue Lin, et al.
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DISCUSSION
Table 2.Distribution of Current Medications and Comorbidities of the Two Study Groups
Non-recurrent group Recurrent group
pvalue
(n = 159) (n = 74)
Medications
Benzodiazepines 23 (14.5) 22 (29.7) 0.008*
Renin-angiotensin system blockers 85 (53.5) 47 (63.5) 0.158
Calcium channel blockers 57 (36.1) 16 (21.6) 0.033*
Alpha-blocker agents 10 (6.3) 11 (14.9) 0.048*
Beta-blocker agents 21 (13.2) 30 (40.5) < 0.001*
Diuretics 33 (20.8) 39 (52.7) < 0.001*
Insulin 46 (28.9) 20 (27.0) 0.876
Oral anti-diabetic agents 116 (73.0) 55 (74.3) 0.875
Sulfonylurea 51 (32.1) 33 (44.6) 0.079
Meglitinde 53 (33.3) 21 (28.4) 0.546
Metformin 60 (37.7) 32 (43.2) 0.472
Thiazolidinedionesa
� 8 (5.0) 3 (4.1) 1.000
Lipid lowering 34 (21.4) 19 (25.7) 0.504
Polypharmacy 71 (44.7) 52 (70.3) < 0.001*
Comorbidities 
Hypertension 127 (79.9) 65 (87.8) 0.195
Coronary artery disease 50 (31.4) 45 (60.8) < 0.001*
Congestive heart failure 43 (27.0) 27 (36.5) 0.168
Chronic obstructive lung disease 9 (5.7) 5 (6.8) 0.771
Dyslipidemia 41 (25.8) 19 (25.7) 1.000
Infection 37 (23.3) 35 (47.3) < 0.001*
End-stage renal diseasea
� 5 (3.1) 7 (9.5) 0.056
Cancer 17 (10.7) 8 (10.8) 1.000
Cirrhosisa
� 2 (1.3) 3 (4.1) 0.330
Alcoholisma
� 5 (3.1) 6 (8.2) 0.105
Data expressed as number (%). 
*p< 0.05.
�Fisher’s exact test.for severe hypoglycemia. Our study suggests that there is a
subset of patients, presenting to the ED with severe hypo-
glycemia and certain risk factors, who should be admitted
due to a greater risk of recurrent hypoglycemia. 
About two-thirds of patients with diabetes who were
admitted to the hospital due to a hypoglycemic coma did
not develope recurrent hypoglycemia. Previous studies
have focused on patients treated in the ED who then return
for recurrent hypoglycemia. In these studies, the accu-
mulated recurrent hypoglycemia rates has been described
as 6.1% by Socransky, et al.,
6 9% by Mechem, et al.,
14 and
10.14% by Carter, et al.
15 We focused on the hospital course
of patients admitted due to severe hypoglycemia. As a
result, we estimate a rate of recurrent hypoglycemia of
14.7% derived from the number of patients presenting to
the ED with hypoglycemia and 31.8% admitted that subse-
quently developed recurrent hypoglycemia, suggesting a
higher rate of recurrent hypoglycemia than previously
Risk Factors for Recurrent Hypoglycemia
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Table 3. Univariate Logistic Regression Analysis for Possible Risk Factors Associated with Recurrent 
Hypoglycemia 
OR 95% CI pvalue
Duration of diabetes (per yr) 1.04 1.01 - 1.08 < 0.012*
White blood cell count (/µL) 1.11 1.03 - 1.20 0.008*
Hemoglobin(mg/dL) 0.80 0.68 - 0.93 0.004*
Estimated GFR (per mL/min)  0.96 0.95 - 0.98 < 0.001*
Serum creatinine (per mg/dL)  1.76 1.43 - 2.17 < 0.001*
BUN (per mg/dL)  1.03 1.01 - 1.05 < 0.001*
Albumin (per mg/dL)  0.55 0.34 - 0.90 0.017*
Loss of recent meal
No 1.00 - 
Yes 3.50 1.97 -  6.22 < 0.001*
Benzodiazepines
No 1.00 - 
Yes 2.50 1.29 - 4.87 0.007*
Calcium channel blockers          
No 1.00 - 
Yes 0.49 0.26 - 0.93 0.029*
Alpha - blockers
No 1.00 - 
Yes 2.60 1.05 - 6.44 0.039*
Beta - blockers
No 1.00 - 
Yes 4.48 2.33 - 8.61 < 0.001*
Diuretics
No 1.00 - 
Yes 4.26 2.34 - 7.72 < 0.001*
Polypharmacy
No 1.00 - 
Yes 2.93 1.63 - 5.28 < 0.001*
Coronary artery disease
No 1.00 - 
Yes 3.38 1.91 - 6.01 < 0.001*
Infection
No 1.00 - 
Yes 2.96 1.65 - 5.32 < 0.001*
BUN, blood urea nitrogen; CI, confidence interval; GFR, glomerular filtration rate; OR, odds ratio.
*p< 0.05.Yen-Yue Lin, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 3   May 2010 372
appreciated.
Once further analyzed with a multiple logic regression
analysis, we found that loss of a recent meal was a signifi-
cant risk factor for recurrent hypoglycemia. Restricted
carbohydrate intake had previously been noted as a predis-
posing factor for drug-induced hypoglycemia.
2 Reduced
carbohydrate intake can lead to a low energy reservoir,
potentiating the development of severe hypoglycemia.
2
Renal insufficiency may lead to reduced renal gluconeo-
genesis and energy intake, as well as a longer half-life of
medications that primarily require kidney elimination.
16,17
Moreover, CAD and infection were additional risk factors
identified. CAD may be a marker for dyslipidemia, which
is associated with insulin resistance and metabolic abnor-
malities.
18 Infection has long been recognized as a risk
factor for hyper- and hypoglycemia in diabetic patients.
2,9,19
Inflammatory stress from endotoxins,
20 fever, and increased
metabolism all increase energy consumption. In a prolonged
infection, basal glucose production may increase and
insulin resistance may develop with or without the presence
Table 4.Multivariate Logistic Regression Analysis for Risk Factors Associated with Recurrent Hypoglycemia
OR 95% CI pvalue
Age (per yr) 1.02 0.98 - 1.06 0.378
Gender                                             
Female 1.00 - 
Male 0.56 0.25 - 1.23 0.151
Hemoglobin (mg/dL) 0.95 0.75 - 1.20 0.652
Estimated GFR (per mL/min)  0.97 0.95 - 0.98 < 0.001*
Albumin (per mg/dL)  0.85 0.48 - 1.50 0.577
Loss of recent meal
No 1.00 - 
Yes 3.93 1.82 - 8.50 < 0.001*
Benzodiazepines
No 1.00 - 
Yes 2.40 0.96 - 6.01 0.055
Calcium channel blockers
No 1.00 - 
Yes 0.19 0.08 - 0.46 < 0.001*
Alpha - blockers
No 1.00
Yes 2.33 0.60 - 8.97 0.219
Beta - blockers
No 1.00 - 
Yes 1.98 0.83 - 4.71 0.124
Diuretics
No 1.00 - 
Yes 1.94 0.86 - 4.38 0.109
Coronary artery disease
No 1.00 - 
Yes 2.30 1.04 - 5.10 0.041*
Polypharmacy
No 1.00 - 
Yes 0.95 0.41 - 2.18 0.901
Infection
No 1.00 - 
Yes 2.40 1.08 - 5.30 0.032*
BUN, blood urea nitrogen; CI, confidence interval; GFR, glomerular filtration rate; OR, odds ratio.
*p< 0.05.of hyperglycemia.
21,22
The only identifiable protective factor for the recurrence
of hypoglycemia was the use of CCBs. It is well known
that CCBs are less likely to have metabolic effects. Tsukuda,
et al.
23 found nifedipine could improve diabetes-associated
cognitive impairment. CCBs may also be used in the
treatment of hyperinsulinemia hypoglycemia in children.
24
However, CCBs as a protective factor for recurrent hypo-
glycemia has not been reported before, and currently we
are unable to explain this unique finding. Further studies
are needed to validate this observation.  
We have also found that patients who had a longer
duration of diabetes, leukocytosis, hypoalbuminemia, the
use of certain medications (benzodiazepines, alpha-blockers,
beta-blockers, and diuretics), as well polypharmacy,
tended to have recurring hypoglycemia during hospitali-
zation. A longer duration of diabetes may be associated
with a defect in, or blunting of, the counter-regulatory
response to hypoglycemia.
9 In addition to poor nutrition,
albumin levels are impacted by other factors including
inflammation, infection, and trauma. Providing adequate
nutrition in the setting of inflammation, infection, or trauma
does not improve albumin levels alone; however, inade-
quate nutrition negatively impacts albumin synthesis.
Mediators of inflammatory responses alter hepatic protein
synthesis and albumin metabolism leading to a net protein
loss followed by anorexia and decreased nutritional
intake.
9,25 Hypoalbuminemia in the recurrent hypoglycemia
group may be a marker for undiagnosed inflammation or
infection and for increased morbidity and mortality.
9,25
Patients with recurrent hypoglycemia were also at greater
risk for longer hospital stays, and hypoalbuminemia has
also been associated with longer hospital stays.
26 Benzo-
diazepines, such as alprazolam, have been demonstrated to
reduce the neuroendocrine response to insulin-induced
hypoglycemia in humans
27 and reduce the plasma catechola-
mine response to exercise stress.
28 The long-term use of
benzodiazepines may blunt the response to repeated low
levels of serum glucose. Several anti-hypertensive agents,
such as RASBs, beta-blockers, and diuretics are associated
with recurrent hypoglycemia.
29-31 Although beta-blockers
showed no significant effect after multiple logistic regres-
sion in our study, non-selective beta-blockers have been
reported to cause severe hypoglycemia in diabetic and
non-diabetic patients.
32 Beta-blockers may decrease the
awareness of hypoglycemia and blunt counter-regulation.
30
Using selective beta-blockers may lessen the risk of induc-
ing hypoglycemia.
33,34
RASB use in our study population was high (56.7%),
and diuretics have been associated with glucose intolerance
and insulin resistance in diabetic patients.
35,36 Although
there are some ADAs with a duration of action as long as
72 hours, we did not find use of these drugs in our study
population. We found that polypharmacy was a significant
risk factor for recurrent hypoglycemia, consistent with
other studies. This is a particular problem for the elderly.
Ben-Ami, et al.
2, in their study of 102 diabetic patients on
ADAs, found that 15% of the 93 patients at risk for a drug-
induced hypoglycemic coma were medicated with addi-
tional drugs known to potentiate hypoglycemia such as
beta-blockers, cimetidine, and aspirin. Shorr, et al.
9 in their
retrospective cohort study of 586 persons with a first episode
of serious hypoglycemia found that the use of 5 or more
medications was a risk factor in the development of serious
hypoglycemia. No patient was treated with glucagon in
this study, since we do not routinely administer glucagon
to treat hypoglycemia at our institution, and the emergency
medicine technicians are not allowed to use glucagon in
Taiwan. 
Limitations
The study design is a non-randomized observational
retrospective study with a small study population, and out-
of-hospital and ED treatment were also not standardized.
There is selection bias, as the patients admitted for severe
hypoglycemia were felt to be at greater risk for developing
recurrent hypoglycemia as compared to those discharged;
however, the reasons for admission were unable to be exa-
mined, as there were no standard admission guidelines. As
a result, the incidence of recurrent hypoglycemia for all
patients presenting to the ED can only be estimated. The
underlying reason for the hypoglycemia was not included
as a variable, and this may have some impact on the out-
comes. Loss of a recent meal could not be calculated
accurately because this information was based on the
patient’s memory (recall bias). 
In conclusion, there may be a subset of patients with
severe hypoglycemia and certain risk factors for recurrent
hypoglycemia who should be admitted. These risk factors
include loss of a recent meal, renal insufficiency, CAD,
and infection. The use of CCBs seemed to be a protective
factor for the development of recurrent hypoglycemia.
Further prospective studies regarding the use of these risk
factors for the disposition of diabetic patients presenting to
the ED with severe hypoglycemia are needed to validate
these findings.    
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